Stock Analiz

TG Therapeutics, Inc. (TGTX) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

TG Therapeutics’s revenue went from $152000 in fiscal 2016 to $616M in fiscal 2025, growth of about 151.7% a year.

Net income in fiscal 2025 was $447M, a net margin of 72.6%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $898M and net income $106M.

Free cash flow was -$25M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 229% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $152000162017: $152000172018: $152000182019: $152000192020: $152000202021: $7M212022: $3M222023: $234M232024: $329M242025: $616M25$616M
Net income
2016: -$78M162017: -$118M172018: -$173M182019: -$173M192020: -$279M202021: -$348M212022: -$224M222023: $13M232024: $23M242025: $447M25$447M
Free cash flow
2016: -$62M162017: -$94M172018: -$129M182019: -$133M192020: -$215M202021: -$296M212022: -$176M222023: -$31M232024: -$41M242025: -$25M25-$25M
EPS (diluted)
2016: $-1.60162017: $-1.91172018: $-2.30182019: $-1.96192020: $-2.42202021: $-2.63212022: $-1.65222023: $0.09232024: $0.15242025: $2.7725$2.77

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$898M$616M$329M$234M$3M$7M$152000$152000$152000$152000$152000
Gross profit$743M$516M$291M$220M$3M$6M—————
Operating income$193M$123M$42M$21M-$218M-$345M-$274M-$169M-$174M-$119M-$79M
Net income$106M$447M$23M$13M-$224M-$348M-$279M-$173M-$173M-$118M-$78M
EPS (diluted)$0.67$2.77$0.15$0.09$-1.65$-2.63$-2.42$-1.96$-2.30$-1.91$-1.60
R&D$236M$160M$94M$76M$125M$223M$166M$154M$159M$103M$69M
Revenue growth—+87.3%+40.8%+8290.0%−58.4%+4300.7%+0.0%+0.0%+0.0%+0.0%—

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$86M-$25M-$41M-$31M-$176M-$296M-$215M-$133M-$129M-$94M-$62M
Capital spending-$693000-$214000-$45000$0-$14000-$401000-$357000-$131000-$90000-$2000-$344000
Free cash flow$86M-$25M-$41M-$31M-$176M-$296M-$215M-$133M-$129M-$94M-$62M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$200M$91M$9M$0$0——————
Stock-based pay$88M$65M$43M$38M$45M$61M$80M$11M$13M$16M$8M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$142M$311M$218M$162M$315M$605M$140M$69M$85M$45M
Debt—$254M$254M$111M$83M$79M$42M$41M$67000$128000$68875
Equity—$648M$222M$161M$59M$237M$519M$39M$24M$67M$36M
Total assets—$1.1B$578M$330M$194M$380M$626M$163M$84M$97M$55M
Shares (diluted)156M161M160M149M135M132M115M88M75M62M49M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin82.7%83.7%88.3%94.0%90.5%88.2%—————
Operating margin21.5%20.0%12.7%8.8%-7839.0%-5154.3%-180000.0%-111200.0%-114700.0%-78100.0%-51953.3%
Net margin11.8%72.6%7.1%5.4%-8036.3%-5204.1%-183800.0%-113700.0%-114100.0%-77944.7%-51482.2%
FCF margin9.5%-4.0%-12.3%-13.4%-6326.2%-4425.7%-141400.0%-87458.6%-84878.3%-61685.5%-40744.1%
ROIC—10.8%8.1%7.4%-154.1%-109.0%-48.7%-212.9%-723.6%-176.9%-219.7%
ROE—69.0%10.5%7.9%-382.0%-146.8%-53.8%-447.7%-721.8%-176.8%-218.2%

Frequently asked questions

What is TG Therapeutics’s annual revenue?

$616M in fiscal 2025 and $898M over the twelve months to September 30, 2026.

How much profit does TG Therapeutics make?

Net income was $447M in fiscal 2025 (net margin 72.6%).

Is TG Therapeutics’s revenue growing?

Yes: revenue rose 87.3% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.